Correlation Between Tumor Growth Delay and Expression of Cancer and Host VEGF, VEGFR2, and Osteopontin in Response to Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 3, 2008, Pages 918-926

  Solberg, Timothy D ^a,b   Nearman, Jessica ^a   Mullins, John ^a   Li, Sicong ^a   Baranowska Kortylewicz, Janina ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Osteopontin; Stereotactic body radiotherapy; Vascular endothelial growth factor; VEGF; VEGFR2

Indexed keywords

CELLS; CYTOLOGY; ELECTROTHERAPEUTICS; ENDOTHELIAL CELLS; PATIENT TREATMENT; RADIOTHERAPY;

ANGIOGENESIS; ANTI-ANGIOGENIC THERAPIES; ATHYMIC MICE; CANCER CELLS; CO-EXPRESSION; DOSE RATES; LATE EFFECTS; OSTEOPONTIN; PARACRINE; POST-TREATMENT MONITORING; STEREOTACTIC BODY RADIOTHERAPY; STROMAL CELLS; TUMOR DOUBLING TIME; TUMOR GROWTH; TUMOR MODELS; TUMOR RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR REPAIR; VEGF; VEGFR2;

TUMORS;

OSTEOPONTIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; STROMA CELL; TUMOR GROWTH; UPREGULATION;

ADENOCARCINOMA; ANIMALS; CELL DIVISION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASMS; OSTEOPONTIN; RNA, MESSENGER; SKIN NEOPLASMS; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 52949107240     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1925     Document Type: Article

References (43)

1. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
2. Kozin S.V., Boucher Y., Hicklin D.J., et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61 (2001) 39-44
3. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
4. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
5. Zips D., Hessel F., Krause M., et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 61 (2005) 908-914
6. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11 (2005) 835-842
7. Maurel J., Martin-Richard M., Conill C., et al. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1391-1398
8. Willett C.G., Duda D.G., diTomaso E., et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 4 (2007) 316-321
9. Senan S., and Smit E.F. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12 (2007) 465-477
10. Horsman M.R., and Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66 (2006) 11520-11539
11. Czito B.G., Bendell J.C., Willett C.G., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 68 (2007) 472-478
12. Gupta V.K., Jaskowiak N.T., Beckett M.A., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8 (2002) 47-54
13. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
14. Brazelle W.D., Shi W., and Siemann D.W. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 836-841
15. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Squamous cell head and neck cancer: Evidence of angiogenic regeneration during radiotherapy. Anticancer Res 21 (2001) 4301-4309
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
17. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
18. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
19. Senger D.R., Ledbetter S.R., Claffey K.P., et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149 (1996) 293-305
20. Hill R.P. Targeted treatment: Insights from studies of osteopontin and hypoxia. Lancet Oncol 6 (2005) 733-734
21. Witte L., Hicklin D.J., Zhu Z., et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17 (1998) 155-161
22. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 5 (2000) 3-10
23. Gille H., Kowalski J., Li B., et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J Biol Chem 276 (2001) 3222-3230
24. Hovinga K.E., Stalpers L.J., van Bree C., et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines-A clue to radioresistance?. J Neurooncol 74 (2005) 99-103
25. Stopeck A., Sheldon M., Vahedian M., et al. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8 (2002) 2798-2805
26. Bonner J.A., Giralt J., Harari P.M., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 22 (2004) 5507
27. Donker M., Van Furth W.R., Mulder-Van Der Kracht S., et al. Negligible radiation protection of endothelial cells by vascular endothelial growth factor. Oncol Rep 18 (2007) 709-714
28. Heissig B., Rafii S., Akiyama H., et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202 (2005) 739-750
29. Solberg T.D., DeSalles A.A.F., Hovda D., et al. A universal, multi-modality localization system for animal radiosurgery. Acta Neurochir 62 (1994) 28-32
30. Sun B., DeSalles A.A.F., Medin P., et al. Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery. Exp Neurol 154 (1998) 691-695
31. Lee J.C., Chow N.H., Wang S.T., et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36 (2000) 748-753
32. Takahashi Y., Kitadai Y., Bucana C.D., et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (1995) 3964-3968
33. Manders P., Beex L.V., Tjan-Heijnen V.C., et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 87 (2002) 772-778
34. Fontanini G., Lucchi M., Vignati S., et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. J Natl Cancer Inst 89 (1997) 881-886
35. Gorski D.H., Leal A.D., and Goydos J.S. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg 197 (2003) 408-418
36. Vergis R., Corbishley C.M., Norman A.R., et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9 (2008) 342-351
37. Plate K.H., Breier G., Weich H.A., et al. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59 (1994) 520-529
38. Neuchrist C., Erovic B.M., Handisurya A., et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111 (2001) 1834-1841
39. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
40. Dias S., Hattori K., Heissig B., et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 98 (2001) 10857-10862
41. Ferrer F.A., Miller L.J., Lindquist R., et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54 (1999) 567-572
42. Alitalo K., and Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1 (2002) 219-227
43. Shijubo N., Uede T., Kon S., et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160 (1999) 1269-1273